Condition: Locally Advanced/Metastatic Solid Tumors · Sponsor: InSilico Medicine Hong Kong Limited
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
This description comes directly from the study's public registry record.
Johnny Ju · +86 021-50831718 · Insilico-Clinicaltrial@insilico.ai
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Smilow Cancer Hospital at Yale New Haven Breast Center | New Haven, Connecticut, United States | Recruiting |
| Community Cancer Center North | Indianapolis, Indiana, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-sen university cancer center | Guangzhou, Guangdong, China | Recruiting |
| Jiangsu Provincial People's Hospital | Nanjing, Jiangsu, China | Recruiting |
| Shanghai Gobroad Cancer Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06414460